Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

@inproceedings{Schwarz2018ResectablePA,
  title={Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)},
  author={Lilian Schwarz and D{\'e}wi Vernerey and J -B Bachet and J. J. Tuech and Fabienne Portales and Pierre Alain Michel and Ant{\'o}nio H. S. Cunha},
  booktitle={BMC Cancer},
  year={2018}
}
BackgroundAt time of diagnosis, less than 10% of patients with pancreatic adenocarcinomas (PDAC) are considered to be immediately operable (i.e. resectable). Considering their poor overall survival (OS), only tumours without vascular invasion (NCCN 2017) should be considered for resection, i.e. those for which resection with disease-free margins (R0) is theoretically possible in absence of presurgery treatment. With regard to high R1 rates and undetectable locoregional and/or metastatic… CONTINUE READING
BETA
2
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 94 REFERENCES

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

  • Journal of the National Comprehensive Cancer Network : JNCCN
  • 2017
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

a novel grading system applied to 633 patients Schwarz et al

ML DeOliveira, JM Winter, M Schafer, surgery et al. Assessment of complications after pancreatic
  • BMC Cancer
  • 2018
VIEW 1 EXCERPT

Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2017
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…